147 related articles for article (PubMed ID: 38683375)
21. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
[TBL] [Abstract][Full Text] [Related]
22. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
[TBL] [Abstract][Full Text] [Related]
23. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
Abdallah MA; Kuo YF; Asrani S; Wong RJ; Ahmed A; Kwo P; Terrault N; Kamath PS; Jalan R; Singal AK
J Hepatol; 2021 Jun; 74(6):1355-1361. PubMed ID: 33326814
[TBL] [Abstract][Full Text] [Related]
24. [Hepatocellular carcinoma: impact of waiting list and pre-operative treatment strategies on survival of cadaveric liver transplantation in pre-MELD era in one center in Brazil].
Freitas AC; Parolin MB; Stadnik L; Coelho JC
Arq Gastroenterol; 2007; 44(3):189-94. PubMed ID: 18060269
[TBL] [Abstract][Full Text] [Related]
25. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
26. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
[TBL] [Abstract][Full Text] [Related]
27. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
Am J Transplant; 2019 Aug; 19(8):2210-2218. PubMed ID: 30861298
[TBL] [Abstract][Full Text] [Related]
28. HCC patients suffer less from geographic differences in organ availability.
Schuetz C; Dong N; Smoot E; Elias N; Schoenfeld DA; Markmann JF; Yeh H
Am J Transplant; 2013 Nov; 13(11):2989-95. PubMed ID: 24011291
[TBL] [Abstract][Full Text] [Related]
29. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
Park SJ; Freise CE; Hirose R; Kerlan RK; Yao FY; Roberts JP; Vagefi PA
Clin Transplant; 2012; 26(4):E359-64. PubMed ID: 22693962
[TBL] [Abstract][Full Text] [Related]
31. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
[TBL] [Abstract][Full Text] [Related]
32. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
Goldberg D; Mantero A; Newcomb C; Delgado C; Forde KA; Kaplan DE; John B; Nuchovich N; Dominguez B; Emanuel E; Reese PP
J Hepatol; 2021 Jun; 74(6):1398-1406. PubMed ID: 33453328
[TBL] [Abstract][Full Text] [Related]
33. List and liver transplant survival according to waiting time in patients with hepatocellular carcinoma.
Salvalaggio PR; Felga G; Axelrod DA; Della Guardia B; Almeida MD; Rezende MB
Am J Transplant; 2015 Mar; 15(3):668-77. PubMed ID: 25650130
[TBL] [Abstract][Full Text] [Related]
34. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
Patel MS; Kohn R; Kratz JR; Shah JA; Markmann JF; Vagefi PA
J Am Coll Surg; 2015 Jun; 220(6):1001-7. PubMed ID: 25868408
[TBL] [Abstract][Full Text] [Related]
35. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
[TBL] [Abstract][Full Text] [Related]
36. Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score.
Vitale A; Huo TL; Cucchetti A; Lee YH; Volk M; Frigo AC; Cescon M; Tuci F; Pinna AD; Cillo U
Ann Surg Oncol; 2015; 22(6):1901-7. PubMed ID: 25234023
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
Gutin L; Yao F; Dodge JL; Grab J; Mehta N
JAMA Netw Open; 2019 Aug; 2(8):e1910326. PubMed ID: 31469395
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients.
Sayiner M; Stepanova M; De Avila L; Golabi P; Racila A; Younossi ZM
Dig Dis Sci; 2020 Feb; 65(2):416-422. PubMed ID: 31451982
[TBL] [Abstract][Full Text] [Related]
39. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
[TBL] [Abstract][Full Text] [Related]
40. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts.
Chan SC; Sharr WW; Chok KS; Chan AC; Lo CM
Transplantation; 2013 Dec; 96(11):995-9. PubMed ID: 23924774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
